Stock price performance of Amicus Therapeutics, Inc. is analyzed for various periods using several stock trading signals. The stock price have dropped -37.28% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -17.81% . Looking at the past 52 week period, the stock price is down -3.67% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Amicus Therapeutics, Inc. has a negative value of -41.18 compared to overall market performance. For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a 20-day Moving Average of 0.02% and the 50-Day Moving Average is 12.24%.The 200 Day SMA reached 19.59%
Amicus Therapeutics, Inc. is having a Relative Strength Index of 56.22 which indicates the stock is not yet over sold or over bought based on the technical indicators. Stocks of Amicus Therapeutics, Inc. (NASDAQ:FOLD) rallied by 6.85% during the past week but lost 0.17% on a 4-week basis. The company has outperformed the S&P 500 by 6.72% in the past week but underperformed the index by 1.06% in the last 4 weeks.
Company has reported several Insider transactions to the SEC, on Jan 17, 2017, Hung Do (Chief Science Officer) sold 25,000 shares at 6.00 per share price.On Nov 10, 2016, Daphne Quimi (SVP, Finance) sold 8,546 shares at 8.00 per share price.On Sep 22, 2016, William D Iii Baird (Chief Financial Officer) sold 20,500 shares at 8.00 per share price.
Amicus Therapeutics Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.33 EPS for the quarter, missing the analyst consensus estimate by $ -0.02. Analyst had a consensus of $-0.31. The company had revenue of $2.10 million for the quarter, compared to analysts expectations of $2.16 million.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Upgraded by Robert W. Baird on Jan 24, 2017 to Outperform, Raises Price Target to $ 10 from a previous price target of $7 .
Amicus Therapeutics, Inc. (NASDAQ:FOLD) : On Friday heightened volatility was witnessed in Amicus Therapeutics, Inc. (NASDAQ:FOLD) which led to swings in the share price. The stock opened for trading at $5.64 and hit $5.825 on the upside , eventually ending the session at $5.77, with a gain of 2.12% or 0.12 points. The heightened volatility saw the trading volume jump to 2,712,481 shares. The 52-week high of the share price is $9.8306 and the company has a market cap of $823 million. The 52-week low of the share price is at $4.41 .
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.